Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pharmacy Costs topic
No spam. Unsubscribe anytime.
Board hears pharmacy briefing: USI says GLP-1s are the Consortium's primary pharmacy cost driver
Summary
USI staff told the board that GLP-1 weight-loss drugs are the primary pharmacy cost driver for the Consortium, discussed TrumpRX.gov (43 cash-only medications) and outlined options such as carved-out coverage or population health programs.
Chris Laverty of USI presented the "State of Pharmacy," telling the board that GLP-1 medications are the primary cost driver for the Consortium's pharmacy spend. Laverty also discussed the emergence of oral tablet GLP-1 weight-loss drugs and explained TrumpRX.gov's limited offering: "Only covers 43 medications" and operates on a cash-only basis, according to the presentation.
Laverty outlined potential strategies the board could consider to manage pharmaceutical costs, including carving out weight-loss drugs, stronger population health programs focused on diabetes and weight management, and behavioral interventions. The presenter noted a projected scenario in which weight-loss GLP-1s "may cut costs by 50% in January of 2027," which the minutes record as a presenter projection rather than a definitive guarantee.
